Anish Amin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anish Amin has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Venkata Sagi
Baptist Health, Jacksonville, FL (V.S.).
3 shared publications - Bradley P. Knight
Feinberg School of Medicine, Division of Cardiology Northwestern University Chicago Illinois USA
2 shared publications - Christophe Leclercq
University of Rennes, Rennes, France
2 shared publications - Christopher Wiggenhorn
Medtronic Inc, Mounds View, MN (A.E.T., Y.Z., C.W., S.W.).
2 shared publications - Francis Murgatroyd
King’s College Hospital, London, UK (F.M.).
2 shared publications - Ian Crozier
Christchurch Hospital, Christchurch, New Zealand
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 8 July 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (1) , 27-40
Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2
BACKGROUND: There are sparse high-quality safety and effectiveness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), in which lesions beyond pulmonary vein isolation (PVI) are often placed. In addition, no large trials have used insertable cardiac monitors for continuous rhythm monitoring after ablation in patients with PerAF or after PFA in any atrial fibrillation population. In Phase 2 of the ADVANTAGE AF study (A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation), patients with PerAF underwent PFA for PVI and posterior wall ablation (PWA) and, in a subcohort, cavotricuspid isthmus ablation for typical atrial flutter. METHODS: Patients with PerAF underwent PVI and posterior wall ablation with the pentaspline PFA catheter and cavotricuspid isthmus with a novel focal-linear PFA catheter after intravenous nitroglycerin prophylaxis. Patients were followed up for 1 year with continuous rhythm monitoring after ablation with insertable cardiac monitors to emulate traditional intermittent monitoring for the primary efficacy end point and to examine atrial arrhythmia (AA) burden and episode duration. RESULTS: This 255-patient cohort (age, 66.7±9.3 years; female, 29%; CHA 2 DS 2 -VASc score, 2.4±1.4; body mass index, 30.9±5.3 kg/m 2 ; left atrium diameter, 4.3±0.6 cm) underwent PVI plus posterior wall ablation (99.6%/100% acute success); a subpopulation (n=141; 55.3%) also received cavotricuspid isthmus PFA, with 98.6% achieving bidirectional block without complications (ST-segment changes, ventricular fibrillation). Cavotricuspid isthmus ablation took 8±13 minutes, using 18±6 pulsed field applications and 4±2 mg IV nitroglycerin. The total procedure and atrial dwell times were 105±36 and 59±24 minutes, respectively. Mimicking traditional monitoring, freedom from AA was 73.4% with adverse events in 2.4%, both meeting prespecified end-point criteria. Freedom from recurrent atrial flutter was 97.2%. Detailed analysis of the full insertable cardiac monitor data revealed freedom from AA of ≥30 seconds in 52.0%, and no episode exceeded 24 hours in 94.0% of this PerAF cohort. Both an AA burden >0.1% and longest episode duration >1 hour were predictive of increased health care use. One-year procedural effectiveness was 71.6% and 70.0% using the thresholds of ≤0.1% burden and <1 hour duration, respectively. CONCLUSIONS: In Phase 2 of ADVANTAGE AF, the first multicenter PerAF study of PFA with continuous rhythm monitoring: (1) cavotricuspid isthmus ablation with nitroglycerin prophylaxis was safe and effective, (2) PVI plus posterior wall ablation was safe and effective, and (3) an AA burden <0.1% and AA episode <1 hour duration were end points associated with the lowest health care use. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05443594.
- 8 July 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (1) , 27-40
Top Cited PapersOpen AccessPulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2
BACKGROUND: There are sparse high-quality safety and effectiveness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), in which lesions beyond pulmonary vein isolation (PVI) are often placed. In addition, no large trials have used insertable cardiac monitors for continuous rhythm monitoring after ablation in patients with PerAF or after PFA in any atrial fibrillation population. In Phase 2 of the ADVANTAGE AF study (A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation), patients with PerAF underwent PFA for PVI and posterior wall ablation (PWA) and, in a subcohort, cavotricuspid isthmus ablation for typical atrial flutter. METHODS: Patients with PerAF underwent PVI and posterior wall ablation with the pentaspline PFA catheter and cavotricuspid isthmus with a novel focal-linear PFA catheter after intravenous nitroglycerin prophylaxis. Patients were followed up for 1 year with continuous rhythm monitoring after ablation with insertable cardiac monitors to emulate traditional intermittent monitoring for the primary efficacy end point and to examine atrial arrhythmia (AA) burden and episode duration. RESULTS: This 255-patient cohort (age, 66.7±9.3 years; female, 29%; CHA 2 DS 2 -VASc score, 2.4±1.4; body mass index, 30.9±5.3 kg/m 2 ; left atrium diameter, 4.3±0.6 cm) underwent PVI plus posterior wall ablation (99.6%/100% acute success); a subpopulation (n=141; 55.3%) also received cavotricuspid isthmus PFA, with 98.6% achieving bidirectional block without complications (ST-segment changes, ventricular fibrillation). Cavotricuspid isthmus ablation took 8±13 minutes, using 18±6 pulsed field applications and 4±2 mg IV nitroglycerin. The total procedure and atrial dwell times were 105±36 and 59±24 minutes, respectively. Mimicking traditional monitoring, freedom from AA was 73.4% with adverse events in 2.4%, both meeting prespecified end-point criteria. Freedom from recurrent atrial flutter was 97.2%. Detailed analysis of the full insertable cardiac monitor data revealed freedom from AA of ≥30 seconds in 52.0%, and no episode exceeded 24 hours in 94.0% of this PerAF cohort. Both an AA burden >0.1% and longest episode duration >1 hour were predictive of increased health care use. One-year procedural effectiveness was 71.6% and 70.0% using the thresholds of ≤0.1% burden and <1 hour duration, respectively. CONCLUSIONS: In Phase 2 of ADVANTAGE AF, the first multicenter PerAF study of PFA with continuous rhythm monitoring: (1) cavotricuspid isthmus ablation with nitroglycerin prophylaxis was safe and effective, (2) PVI plus posterior wall ablation was safe and effective, and (3) an AA burden <0.1% and AA episode <1 hour duration were end points associated with the lowest health care use. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05443594.
- Open Access
- 3 July 2025
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 11 (8) , 1877-1879
Characteristics of Extravascular Implantable Cardioverter-Defibrillator Implantation
- 3 July 2025
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 11 (8) , 1877-1879
Open AccessCharacteristics of Extravascular Implantable Cardioverter-Defibrillator Implantation
- Top Cited PapersOpen Access
- 28 January 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (4) , 322-332
Performance and Safety of the Extravascular Implantable Cardioverter Defibrillator Through Long-Term Follow-Up: Final Results From the Pivotal Study
BACKGROUND: Substernal lead placement of the extravascular implantable cardioverter defibrillator (EV ICD) permits both defibrillation at thresholds similar to those seen with transvenous implantable cardioverter defibrillators and effective anti-tachycardia pacing (ATP) while avoiding the vasculature and associated complications. The global Pivotal study has shown the EV ICD system to be safe and effective through 6 months, but long-term experience has yet to be published. Our aim was to report the performance and safety of the EV ICD system throughout the study. METHODS: The EV ICD Pivotal study was a prospective, global, single-arm, premarket clinical study. Individuals with a Class I or IIa indication for a single-chamber implantable cardioverter defibrillator per guidelines were enrolled. Freedom from major system- or procedure-related complications and appropriate and inappropriate therapy rates were assessed through 3 years with the Kaplan-Meier method. ATP success was calculated from simple proportions. RESULTS: An implantation was attempted in 316 patients (25.3% female; 53.8±13.1 years of age; 81.6% primary prevention; left ventricular ejection fraction, 38.9±15.4%). Of 299 patients with a successful implantation, 24 experienced 82 spontaneous arrhythmic episodes that were appropriately treated with ATP only (38, 46.3%), shock only (34, 41.5%), or both (10, 12.2%) for a Kaplan-Meier–estimated rate of first any appropriate therapy of 9.2% at 3 years. ATP was successful in 77.1% (37/48) of episodes, and ATP use significantly increased from discharge to last follow-up visit ( P <0.0001). Shock therapy was successful in 100% (27/27) of discrete, spontaneous ventricular arrhythmias. The inappropriate shock rates at 1 and 3 years were 9.8% and 17.5%, respectively, with P-wave oversensing the predominant cause. No major intraprocedural complications were reported, and the estimated freedom from system- or procedure-related major complications was 91.9% at 1 year and 89.0% at 3 years. The most common major complications were lead dislodgement (10 events; n=9 patients, 2.8%), postoperative wound or device pocket infection (n=8, 2.5%), and device inappropriate shock delivery (n=4, 1.3%). Twenty-four system revisions were performed as a result of major complications related to the EV ICD system or procedure. CONCLUSIONS: From implantation to study completion, the EV ICD Pivotal study demonstrated that a single integrated system with an extravascular lead placed in the substernal space maintains high ATP success, effective defibrillation, and a consistent safety profile. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04060680.
- 28 January 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (4) , 322-332
Top Cited PapersOpen AccessPerformance and Safety of the Extravascular Implantable Cardioverter Defibrillator Through Long-Term Follow-Up: Final Results From the Pivotal Study
BACKGROUND: Substernal lead placement of the extravascular implantable cardioverter defibrillator (EV ICD) permits both defibrillation at thresholds similar to those seen with transvenous implantable cardioverter defibrillators and effective anti-tachycardia pacing (ATP) while avoiding the vasculature and associated complications. The global Pivotal study has shown the EV ICD system to be safe and effective through 6 months, but long-term experience has yet to be published. Our aim was to report the performance and safety of the EV ICD system throughout the study. METHODS: The EV ICD Pivotal study was a prospective, global, single-arm, premarket clinical study. Individuals with a Class I or IIa indication for a single-chamber implantable cardioverter defibrillator per guidelines were enrolled. Freedom from major system- or procedure-related complications and appropriate and inappropriate therapy rates were assessed through 3 years with the Kaplan-Meier method. ATP success was calculated from simple proportions. RESULTS: An implantation was attempted in 316 patients (25.3% female; 53.8±13.1 years of age; 81.6% primary prevention; left ventricular ejection fraction, 38.9±15.4%). Of 299 patients with a successful implantation, 24 experienced 82 spontaneous arrhythmic episodes that were appropriately treated with ATP only (38, 46.3%), shock only (34, 41.5%), or both (10, 12.2%) for a Kaplan-Meier–estimated rate of first any appropriate therapy of 9.2% at 3 years. ATP was successful in 77.1% (37/48) of episodes, and ATP use significantly increased from discharge to last follow-up visit ( P <0.0001). Shock therapy was successful in 100% (27/27) of discrete, spontaneous ventricular arrhythmias. The inappropriate shock rates at 1 and 3 years were 9.8% and 17.5%, respectively, with P-wave oversensing the predominant cause. No major intraprocedural complications were reported, and the estimated freedom from system- or procedure-related major complications was 91.9% at 1 year and 89.0% at 3 years. The most common major complications were lead dislodgement (10 events; n=9 patients, 2.8%), postoperative wound or device pocket infection (n=8, 2.5%), and device inappropriate shock delivery (n=4, 1.3%). Twenty-four system revisions were performed as a result of major complications related to the EV ICD system or procedure. CONCLUSIONS: From implantation to study completion, the EV ICD Pivotal study demonstrated that a single integrated system with an extravascular lead placed in the substernal space maintains high ATP success, effective defibrillation, and a consistent safety profile. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04060680.
- Open Access
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Continuous QT interval monitoring using insertable cardiac monitors during antiarrhythmic loading hospitalization: Results from the "LINQ QT" Study
Background: QT interval prolongation is associated with the development of potentially lethal cardiac arrhythmias. An implantable cardiac monitor (ICM) capable of longitudinal QT monitoring may allow for mobile assessment of dynamic changes in QT and assist in predicting long term cardiotoxicity. Objective: Determine feasibility of continuous QTc interval monitoring in patients with ICM hospitalized for antiarrhythmic drug loading. Methods: The previously described QT detection algorithm for an ICM determines the QT interval for every beat thus providing continuous long-term QT trends. QT intervals detected from continuously collected ICM ECG data from patients enrolled in a prospective clinical study from three sites was analyzed with the primary objective of studying the long-term QT interval trends in patients undergoing antiarrhythmic drug loading in an inpatient setting. The ICM ECG was processed through the QT detection algorithm which calculates the QTc interval for every beat to generate continuous long term QTc trends. Metrics including mean and median QTc, minimum and maximum QTc, and magnitude of QTc change were studied during the hospitalization period. Continuous QTc interval trend is presented from a patient displaying increase in QTc interval following antiarrhythmic drug loading during the hospitalization period. Results: 5 out of 17 patients enrolled (avg. age 71±7.3 years, 40% females) in the QT clinical study had continuous telemetered ICM ECG data available during the index antiarrhythmic loading hospitalization period. All patients were loaded with Sotalol during the hospitalization. All 5 patients had hypertension and atrial fibrillation (AF). 3 patients (60%) had a history of myocardial infarction (MI), congestive heart failure (CHF), and coronary artery disease (CAD) while 1 patient (20%) had diabetes. The magnitude of change in QTc over the hospitalization period was 139±42 msec with over 100 msec QTc change noticed in 4 of 5 patients (80%) (figure 1). Figure 2 shows continuous QTc interval trend observed from a patient (Male; Age:75; history of AF, hypertension, CHF, stroke) from this study showing a continuous increase in QTc interval. Overall, there was over 150 msec change in QTc observed for this patient during the hospitalization period. Premature ventricular complexes (PVCs) in a pattern of bigeminy were observed from ICM ECG for a 3-hr period from 12 pm-3 pm following the second antiarrhythmic dose which coupled with QT prolongation could indicate early signs of cardiotoxicity (figure 2). The five static 12-lead ECG measurements taken for this patient during the hospitalization period is also reported with the difference between these 12-lead QTc measurements and algorithm measured QTc being 22±8 msec. Conclusion: ICM QT monitoring performed utilizing a QT interval detection algorithm can provide longitudinal and long-term dynamic QT trends in patients implanted with ICM.
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Open AccessContinuous QT interval monitoring using insertable cardiac monitors during antiarrhythmic loading hospitalization: Results from the "LINQ QT" Study
Background: QT interval prolongation is associated with the development of potentially lethal cardiac arrhythmias. An implantable cardiac monitor (ICM) capable of longitudinal QT monitoring may allow for mobile assessment of dynamic changes in QT and assist in predicting long term cardiotoxicity. Objective: Determine feasibility of continuous QTc interval monitoring in patients with ICM hospitalized for antiarrhythmic drug loading. Methods: The previously described QT detection algorithm for an ICM determines the QT interval for every beat thus providing continuous long-term QT trends. QT intervals detected from continuously collected ICM ECG data from patients enrolled in a prospective clinical study from three sites was analyzed with the primary objective of studying the long-term QT interval trends in patients undergoing antiarrhythmic drug loading in an inpatient setting. The ICM ECG was processed through the QT detection algorithm which calculates the QTc interval for every beat to generate continuous long term QTc trends. Metrics including mean and median QTc, minimum and maximum QTc, and magnitude of QTc change were studied during the hospitalization period. Continuous QTc interval trend is presented from a patient displaying increase in QTc interval following antiarrhythmic drug loading during the hospitalization period. Results: 5 out of 17 patients enrolled (avg. age 71±7.3 years, 40% females) in the QT clinical study had continuous telemetered ICM ECG data available during the index antiarrhythmic loading hospitalization period. All patients were loaded with Sotalol during the hospitalization. All 5 patients had hypertension and atrial fibrillation (AF). 3 patients (60%) had a history of myocardial infarction (MI), congestive heart failure (CHF), and coronary artery disease (CAD) while 1 patient (20%) had diabetes. The magnitude of change in QTc over the hospitalization period was 139±42 msec with over 100 msec QTc change noticed in 4 of 5 patients (80%) (figure 1). Figure 2 shows continuous QTc interval trend observed from a patient (Male; Age:75; history of AF, hypertension, CHF, stroke) from this study showing a continuous increase in QTc interval. Overall, there was over 150 msec change in QTc observed for this patient during the hospitalization period. Premature ventricular complexes (PVCs) in a pattern of bigeminy were observed from ICM ECG for a 3-hr period from 12 pm-3 pm following the second antiarrhythmic dose which coupled with QT prolongation could indicate early signs of cardiotoxicity (figure 2). The five static 12-lead ECG measurements taken for this patient during the hospitalization period is also reported with the difference between these 12-lead QTc measurements and algorithm measured QTc being 22±8 msec. Conclusion: ICM QT monitoring performed utilizing a QT interval detection algorithm can provide longitudinal and long-term dynamic QT trends in patients implanted with ICM.
- Open Access
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Substernal lead removal: experience from the EV ICD pivotal study
Background: The extravascular implantable cardioverter defibrillator (EV ICD) has recently emerged as a new option for guideline indicated ICD patients. Previous study results from the EV ICD Pilot and Pivotal studies have demonstrated that the device can provide safe and effective therapy through chronic follow up. However, less has been reported regarding EV ICD lead removal. Purpose: To report on the experience of lead removal in the EV ICD Pivotal Study. Methods: The EV ICD Pivotal study was an international, prospective, single-arm, premarket clinical study. Patients with a class I or IIa indication for a single-chamber ICD per ESC or ACC/AHA/HRS guidelines were enrolled. Lead removal summary data was reported. Results: Of 316 patients with an implant attempt, (74.7% male, age 53.8±13.1 years, 82% primary prevention, LVEF of 38.9%±15.4%, and NYHA Class I [23.7%] or II/III [65.5%]) 299 were fully implanted; 17 (5.7%) of which had a lead removal procedure (14–752 days post-implant, at 13 sites) with 3 of them having been implanted for more than 1 year. Reasons for lead removal were lead dislodgement (n=7), infection (n=5), high impedance alert due to lead fracture (n=2), pacing indication (n=1), cardiac transplant (n=1), or scheduled sternotomy (n=1). New EV ICD leads were placed in 7/17 (41.2%) patients. No serious adverse events were adjudicated as related to the explant procedures. There was a single observation of incision site haemorrhage, that was resolved with wound care. Additional details on lead removal will be included at the time of presentation. Conclusions: The EV ICD lead was successfully removed 14-752 days post implant. Nine patients were re-implanted with either extravascular or transvenous systems. Longer term extraction data collection is ongoing through the EV ICD Pivotal study and through the EV ICD post-approval study and will continue to provide additional insights.Lead removed 24 months post-implant.
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Open AccessSubsternal lead removal: experience from the EV ICD pivotal study
Background: The extravascular implantable cardioverter defibrillator (EV ICD) has recently emerged as a new option for guideline indicated ICD patients. Previous study results from the EV ICD Pilot and Pivotal studies have demonstrated that the device can provide safe and effective therapy through chronic follow up. However, less has been reported regarding EV ICD lead removal. Purpose: To report on the experience of lead removal in the EV ICD Pivotal Study. Methods: The EV ICD Pivotal study was an international, prospective, single-arm, premarket clinical study. Patients with a class I or IIa indication for a single-chamber ICD per ESC or ACC/AHA/HRS guidelines were enrolled. Lead removal summary data was reported. Results: Of 316 patients with an implant attempt, (74.7% male, age 53.8±13.1 years, 82% primary prevention, LVEF of 38.9%±15.4%, and NYHA Class I [23.7%] or II/III [65.5%]) 299 were fully implanted; 17 (5.7%) of which had a lead removal procedure (14–752 days post-implant, at 13 sites) with 3 of them having been implanted for more than 1 year. Reasons for lead removal were lead dislodgement (n=7), infection (n=5), high impedance alert due to lead fracture (n=2), pacing indication (n=1), cardiac transplant (n=1), or scheduled sternotomy (n=1). New EV ICD leads were placed in 7/17 (41.2%) patients. No serious adverse events were adjudicated as related to the explant procedures. There was a single observation of incision site haemorrhage, that was resolved with wound care. Additional details on lead removal will be included at the time of presentation. Conclusions: The EV ICD lead was successfully removed 14-752 days post implant. Nine patients were re-implanted with either extravascular or transvenous systems. Longer term extraction data collection is ongoing through the EV ICD Pivotal study and through the EV ICD post-approval study and will continue to provide additional insights.Lead removed 24 months post-implant.